UK markets closed
NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.27 -0.21 (-0.27%) GOLD FUTURES
2,321.50 -9.70 (-0.42%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
50,334.90 -282.21 (-0.56%)
HRTX May 2024 3.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:55PM EDT. Market open.
| Previous close | 0.5500 |
| Open | 0.3500 |
| Bid | 0.0000 |
| Ask | 0.3500 |
| Strike | 3.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.2500 - 0.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 379 |
GuruFocus.comHeron Therapeutics Inc (HRTX) Q1 2024 Earnings Overview: Surpasses Revenue Estimates
Improved Financial Metrics and Strategic Partnerships Mark the Quarter
ZacksHeron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ZacksHeron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 75% and 6.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
© 2024 Yahoo. All rights reserved.